TME Pharma NV (XPAR:ALTME) Forward Dividend Yield %: 0.00% (As of Jul. 11, 2026)


What is TME Pharma NV Forward Dividend Yield %?

TME Pharma NV XPAR:ALTME -3.45% Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. The stock has 4 warning signs investors should review. Among 148 Biotechnology companies, TME Pharma NV ranks worse than 675675% on this metric.

As of today (2026-07-11), the Forward Annual Dividend Yield of TME Pharma NV is 0.00%.

As of today (2026-07-11), the Trailing Annual Dividend Yield of TME Pharma NV is 0.00%.

XPAR:ALTME's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Forward Dividend Yield % only.

TME Pharma NV's Dividends per Share for the six months ended in Dec. 2025 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

TME Pharma NV  (XPAR:ALTME) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

TME Pharma NV Forward Dividend Yield % Related Terms

XPAR:ALTME vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, TME Pharma NV's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TME Pharma NV Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TME Pharma NV's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where TME Pharma NV's Forward Dividend Yield % falls into.


TME Pharma NV Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
TME Pharma NV (XPAR:ALTME) has a Forward Dividend Yield % of 0.00% as of Jul. 11, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TME Pharma NV and its competitors. According to the industry distribution chart, TME Pharma NV ranks #999999 out of 148 companies in the Biotechnology industry.
Is TME Pharma NV's Forward Dividend Yield % too high?
TME Pharma NV's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, TME Pharma NV ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does TME Pharma NV's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TME Pharma NV ranks #999999 out of 148 companies for Forward Dividend Yield %. This places TME Pharma NV in the lower half of its industry. The industry median Forward Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.31, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on TME Pharma NV and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TME Pharma NV's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Forward Dividend Yield % is 0.00% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.